Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.03.001 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Luca Malorni und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Italy. Electronic address:…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Farmacéutica.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Italy. Electronic address: Luca.malorni@uslcentro.toscana.it.
- Department of Oncology, Ospedale San Raffaele, Milano, Italy.
- Department of Breast and Thoracic Oncology, IRCCS Istituto Nazionale dei Tumori Fondazione G Pascale, Napoli, Italy.
- Medical Oncology Unit, IRCCS Humanitas Research Hospital and Department of Biomedical Sciences - Humanitas University, Milano, Italy.
- Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico,Aviano, Italy; Department of Medicine, University of Udine, Italy.
- SC Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Förderung
- Novartis Farmacéutica
Zitieren
APA
Malorni, L., Bianchini, G., Caputo, R., Zambelli, A., Puglisi, F., Bianchi, G. V., Del Mastro, L., Paris, I., Montemurro, F., Allegrini, G., Colleoni, M., Tamberi, S., Zamagni, C., Cazzaniga, M. E., Orditura, M., Guarneri, V., Castelletti, D., Benelli, M., Di Marino, M., …, & De Laurentiis, M. (2023). Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.03.001
Vancouver
Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi GV, et al. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.03.001
BibTeX
@article{Malorni2023,
author = {Malorni, Luca and Bianchini, Giampaolo and Caputo, Roberta and Zambelli, Alberto and Puglisi, Fabio and Bianchi, Giulia V and Del Mastro, Lucia and Paris, Ida and Montemurro, Filippo and Allegrini, Giacomo and Colleoni, Marco and Tamberi, Stefano and Zamagni, Claudio and Cazzaniga, Marina E and Orditura, Michele and Guarneri, Valentina and Castelletti, Daniela and Benelli, Matteo and Di Marino, Mariacristina and Arpino, Grazia and De Laurentiis, Michelino},
title = {Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.03.001}
}
EUVIMED